Esteve to acquire Perrigo's rare disease pharma business for up to $295M
Perrigo announced Thursday that Barcelona-based pharma company Esteve Healthcare has agreed to purchase its three rare disease drug assets for as much as €275 million ($295 million).
The marketed therapies for Cushing’s syndrome and adrenocortical carcinoma — Metopirone, Ketoconazole and Lysodren — will be sold for an upfront cash payment of €190 million ($203 million) and up to €85 million ($92 million) in potential sales-based milestones.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
